Stivers, Welch Reintroduce Bill To Prevent Use Of REMS To Delay Generics

July 2, 2015 at 7:02 PM
Reps. Steve Stivers (R-OH) and Peter Welch (D-VT) reintroduced bipartisan legislation aimed at stopping brand drug makers from using restrictive safety designations, known as Risk Evaluation and Mitigation Strategies (REMS), to delay generic drug entry into the market. The reintroduction of the Fair Access for Safe and Timely (FAST) Generics Act drew praise from the generic drug lobby, some unions and pharmacy associations that back efforts to stop brand companies from using restricted distribution networks to deny generic and biosimilar...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.